ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2225

Treatment Outcomes of Newly and Formerly Diagnosed Patients with Fibromyalgia after Fibromyalgia Treatment Program

Juan Jiao1, Connie A. Luedtke2,3, Ann Vincent4 and Terry H. Oh5, 1Rheumatology Department, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, 2Department of Nursing, Mayo Clinic, Rochester, MN, Rochester, MN, 3Department of Nursing, Mayo Clinic, Rochester, MN, 4General Internal Medicine, Mayo Clinic, Rochester, MN, 5Physical Medicine & Rehabilitation, Mayo Clinic, Rochester, MN

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Fibromyalgia and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster II: Clinical Focus

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  We compared treatment outcomes between newly diagnosed versus formerly diagnosed patients seen in the brief interdisciplinary fibromyalgia treatment program (FTP). The FTP includes diagnostic evaluation as well as treatment, focused on cognitive behavioral therapy.

Methods:  We studied 978 fibromyalgia who underwent the FTP and met the 1990 ACR clinical criteria for fibromyalgia. We abstracted the patients’ diagnosis information from electronic medical record. All the 978 patients completed the Fibromyalgia Impact Questionnaire (FIQ) and the Short Form-36 Health Status Questionnaire (SF-36) at baseline.

Results:  Five hundreds thirty-five patients (55%) received diagnosis of fibromyalgia when seen in FTP and were defined as newly diagnosed group. The rest, 443 patients (45%), were previously diagnosed with fibromyalgia and were confirmed to have fibromyalgia at the FTP, were defined as formerly diagnosed group. It had been 3.6 (9.2 SD) years for those formerly diagnosed patients had their fibromylgia diagnosed before they seen in FTP. Those formerly diagnosed patients were more likely to be older, and to have higher BMI and longer duration of fibromyalgia symptoms compared to early diagnosed patients. After adjusting for these differences, no differences were found in the FIQ total score, FIQ subscales, and all the SF-36 subscores between newly and formerly diagnosed patients. After treatment, 313 patients (58.5%) in newly diagnosed group and 224 patients (50.3%) in formerly diagnosed group completed the 6-12 month follow-up questionnaires, and both groups tended to improve excepted for the FIQ depression subscale and SF-36 general health perceptions and role emotional subscores; however, the formerly diagnosed patients had significantly less improvement in the FIQ subscales in work missed days (P=0.04).

Conclusion:  In our clinic sample, included both newly and formerly diagnosed patient with over ½ being newly diagnosed, there was no differences on symptom severity and quality of live between newly and formerly diagnosed fibromyalgia patients. Both groups benefited from the FTP similarly. Brief, interdisciplinary FTP could both benefit incident and prevalent fibromyalgia patients; moreover, these newly diagnosed patients might miss less work days after treatment. Further studies are needed to verify our results and to demonstrate the mechanisms underneath this phenomenon.


Disclosure: J. Jiao, None; C. A. Luedtke, None; A. Vincent, None; T. H. Oh, None.

To cite this abstract in AMA style:

Jiao J, Luedtke CA, Vincent A, Oh TH. Treatment Outcomes of Newly and Formerly Diagnosed Patients with Fibromyalgia after Fibromyalgia Treatment Program [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/treatment-outcomes-of-newly-and-formerly-diagnosed-patients-with-fibromyalgia-after-fibromyalgia-treatment-program/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-outcomes-of-newly-and-formerly-diagnosed-patients-with-fibromyalgia-after-fibromyalgia-treatment-program/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology